Report on Hong Kong-Listed Biotech Companies - April 2023

Published date25 April 2023
Subject MatterHealthcare,Life Sciences,IPO,Publicly-Traded Companies,Biotechnology,Foreign Corporations,Corporate Governance,Capital Markets,HKEx,Hong Kong,Listing Rules,Hong Kong Stock Exchange,Hong Kong Securities and Futures Commission (HKSFC),Initial Public Offerings,Capital Raising
AuthorPaloma Wang,Anthony Pang,Martina To,Kai Sun,Lillian Lian
Law FirmSkadden, Arps, Slate, Meagher & Flom LLP

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT